AMVUTTRA works with your body’s natural system to rapidly knock down TTR. It decreases the amount of TTR protein made in the liver, which leads to fewer harmful amyloid deposits being formed.

AMVUTTRA works to treat the polyneuropathy caused by hATTR amyloidosis, so your world may be within reach.

Patients treated with AMVUTTRA showed significant improvement in nerve function and quality of life at 9 months and continued to improve throughout an 18-month clinical study of 164 patients compared with those who received placebo in a similar study.

At 18 months:

• 48% of patients treated with AMVUTTRA regained some nerve function from the start of treatment compared with 4% of those who received placebo^a

• 57% of patients treated with AMVUTTRA reported better quality of life from the start of treatment compared with 10% of those who received placebo^b

^aNerve function was assessed using a scale called mNIS+7 that measured strength and sensation in the hands, feet, arms, and legs; reflexes; and blood pressure upon standing.

^bQuality of life was evaluated by the Norfolk QoL-DN questionnaire that asked patients about the severity of their polyneuropathy symptoms, how often they experienced them, and what impact they felt they had on their daily lives.

AMVUTTRA is administered 4 times a year by a healthcare professional.

• It is given as an injection under the skin once every 3 months

• The most common side effects in patients treated with AMVUTTRA during the clinical study were pain in the arms or legs (15%), pain in the joints (11%), shortness of breath (7%), and low vitamin A levels (7%)

• Injection site reactions were mild in severity, decreased over time, and occurred in 5 patients (4%)